Comparative diagnostic performance of plasma microbial cell-free DNA sequencing versus amplicon-based blood next-generation sequencing in suspected bloodstream or endovascular infection: a single-center study

2026/01/01 by Mayar Al Mohajer, Todd Lasco · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Bacterial Identification and Susceptibility Testing #Infectious Aortic and Vascular Conditions #Infective Endocarditis Diagnosis and Management

paper · pdf · doi:10.1017/ash.2026.10337

openalex publication_date 2026/01/01 · openalex created_date 2026/03/28 · openalex updated_date 2026/05/21

Abstract

We compared plasma microbial cell-free DNA sequencing (mcfDNAseq) with an amplicon-based blood next-generation sequencing (NGS) assay for 10 patients with suspected bloodstream or endovascular infection. Plasma testing detected pathogens in eight (seven clinically meaningful), whereas amplicon testing was negative in all. Plasma mcfDNAseq provided higher test yield and overall sensitivity.

Discussions

• We compared plasma microbial cell-free DNA sequencing (mcfDNAseq) with an amplicon-based blood next-generation sequencing (NGS) assay in 10 inpatients with suspected BSI. Plasma testing detected patho [bsky, 0 points, 0 comments]

Related

• Clinical utility of serial plasma cell-free DNA metagenomic next-generation sequencing assays
• Impact of Metagenomic Next-Generation Sequencing of Plasma Cell-free DNA Testing in the Management of Patients With Suspected Infectious Diseases
• From Suspected to Rejected: Role of Serial Plasma Microbial Cell-Free DNA Sequencing as a Diagnostic Adjunct in CIED Infections
• Clinical utility of plasma microbial cell-free DNA sequencing for early diagnosis of toxoplasmosis in high-risk patients: a five-patient case series
• Utility of microbial cell-free DNA sequencing in the diagnosis of mycobacterial infections in a quaternary care center